Danon disease in children: view of a pediatric cardiologist

Danon disease is a rare hereditary disease with predominant damage to the heart and skeletal muscles. Danon disease is referred to lysosomal storage disorders with severe, progressive course and it often leads to an early mortality. The main cause of Danon disease is the mutations in the LAMP2 gene in the Xq24–q25 chromosome region. Danon disease has X-linked dominant nature of inheritance; women have a milder phenotype with older heart damage. For the first time the disease was described in boys with cardiomyopathy, severe skeletal myopathy and intellectual deficiency. The article presents up-to-date review on Danon disease and case reports of the cardiology department of the National Medical Research Center for Children’s Health, where 5 male patients were observed from 2014 to 2020, and the average age at diagnosis – 13,2 years. During the lab examination three patients demonstrated a significant increase of the heart failure marker (NT-proBNP) – more than 5 thousand pg/ml, the intracellular enzymes was more than 2,5 norms in 4 patients. The Wolff–Parkinson–White phenomenon is recorded in all patients on the ECG. Echocardiography in one patient showed a rare combination of myocardial hypertrophy and non-compact left ventricular myocardium. 2 patients had a combination of hypertrophic and dilated phenotypes with a reduced ejection fraction on Echo and severe myocardial fibrosis on MRI of the heart, which clinically manifested with chronic heart failure refractory to drug therapy, which required heart transplantation.

1. Boucek D., Jirikowic J., Taylor M. Natural history of Danon disease. Genet Med 2011; 13(6): 563–568. DOI: 10.1097/GIM.0b013e31820ad795

2. Endo Y., Furuta A., Nishino I. Danon disease: a phenotypic expression of LAMP-2 deficiency. Acta Neuropathol 2015; 129(3): 391–398. DOI: 10.1007/s00401-015-1385-4.

3. Леонтьева И.В., Царегородцев Д.А. Болезнь Данона как причина гипертрофической кардиомиопатии. Российский вестник перинатологии и педиатрии 2015; 60(3): 26–30. [Leontyeva I.V., Tsaregorodtsev D.A. Danon’s disease as a cause of hypertrophic cardiomyopathy. Rossiyskiy vestnik perinatologii i pediatrii (Russian Bulletin of Perinatology and Pediatrics) 2015; 60(3): 26–30. (In Russ.)]

4. Rowland T.J., Sweet M.E., Mestroni L., Taylor M.R.G. Danon disease – dysregulation of autophagy in a multisystem disorder with cardiomyopathy. J Cell Sci 2016; 129: 2135–2143. DOI:10.1242/jcs.184770.

5. Human Gene Mutation Database. http://www.hgmd.cf.ac.uk/ac/index.php Ссылка активна активна на 05.04.2021.

6. D’souza R.S., Levandowski C., Slavov D., Graw S.L, Allen L.A., Adler E. et al. Danon Disease: Clinical Features, Evaluation, and Management. Circ Heart Fail 2014; 7(5): 843–849. DOI: 10.1161/CIRCHEARTFAILURE.114.001105.

7. Nishino I., Fu J., Tanji K., Yamada T., Shimojo S., Koori T. et al. Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). J Nature 2000: 24; 406(6798): 906–10. DOI: 10.1038/35022604

8. Danon M.J., Oh S.J., DiMauro S., Manaligod J.R., Eastwood A., Naidu S., Schliselfeld L.H. Lysosomal glycogen storage disease with normal acid maltase. Neurology1981; 31(1): 51–7. DOI: 10.1212/wnl.31.1.51.

9. Gersh B.J., Maron B.J., Bonow R.O., Dearani J.A., Fifer M.A., Link M.S. et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124(24): 2761–2796. DOI: 10.1161/CIR.0b013e318223e230

10. Bertini E., Donati M.A., Broda P., Cassandrini D., Petrini S., Dionisi-Vici C. et al. Phenotypic heterogeneity in two unrelated Danon patients associated with the same LAMP-2 gene mutation. Neuropediatrics 2005; 36(5): 309–13. DOI: 10.1055/s-2005-872844.

11. Arad M., Maron B.J., Gorham J.M., Johnson W.H. Jr., Saul J.P., Perez Atayde A.R. et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med 2005; 352(4): 362–372. DOI: 10.1056/NEJMoa033349.

12. Lipshultz S.E., Law Y.M., Asante-Korang A., Austin E.D., Dipchand A.I., Everitt M.D. et al. Cardiomyopathy in Children: Classification and Diagnosis: A Scientific Statement From the American Heart Association. Circulation 2019; 140(1): e9–e68. DOI: 10.1161/CIR.0000000000000682.

13. Sugie K., Yamamoto A., Murayama K., Oh S.J., Takahashi M., Mora M. et al. Clinicopathological features of genetically confirmed Danon disease. Neurology 2002; 58(12): 1773–8. DOI: 10.1212/wnl.58.12.1773

14. Maron B.J., Roberts W.C., Arad M., Haas T.S., Spirito P., Wright G.B. et al. Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. JAMA.2009; 301(12): 1253–9. DOI: 10.1001/jama.2009.371.

15. Marriott H.J. Electrocardiographic abnormalities, conduction disorders and arrhythmias in primary myocardial disease. Prog Cardiovasc Dis 1964; 7: 99–114. DOI: 10.1016/S0033-0620(64)80013-X.

16. Nucifora G., Miani D., Piccoli G., Proclemer A. Cardiac Magnetic Resonance Imaging in Danon Disease. Cardiology 2012; 121(1): 27–30. DOI: 10.1159/000336448.

17. Dara B.S., Rusconi P.G., Fishman J.E. Danon disease: characteristic late gadolinium enhancement pattern on cardiac magnetic resonance imaging. Cardiol Young 2011; 21(06): 707–709. DOI: 10.1017/s1047951111000564.

18. Rigolli M., Kahn A., Brambatti M., Contijoch F., Adler E. Cardiomyopathy characterization and risk stratification by cardiac magnetic resonance in danon disease. J Am Coll Cardiol 2020; 75 (11 Supplement 1): 1681. DOI: 10.1016/S0735-1097(20)32308-1

19. Леонтьева И.В., Царегородцев Д.А. Лизосом-ассоциированная гипертрофическая кардиомиопатия (болезнь Данона) у двух сибсов. Российский вестник перинатологии и педиатрии 2015; 60(4): 75–82. [Leontyeva I.V., Tsaregorodtsev D.A. Lysosome-associated hypertrophic cardiomyopathy (Danon’s disease) in two siblings. Rossiyskiy vestnik perinatologii i pediatrii (Russian Bulletin of Perinatology and Pediatrics) 2015; 60(4): 75–81. (In Russ.)]

20. Stevens-Lapsley J.E., Kramer L.R., Balter J.E., Jirikowic J., Boucek D., Taylor M. Functional performance and muscle strength phenotypes in men and women with Danon disease. Muscle Nerve 2010; 42(6): 908–14. DOI: 10.1002/mus.21811

21. Charron P., Villard E., Sébillon P., Laforêt P., Maisonobe T., Duboscq-Bidot L. et al. Danon’s disease as a cause of hypertrophic cardiomyopathy: a systematic survey. Heart 2004; 90(8): 842–846. DOI: 10.1136/hrt.2003.029504

22. Schorderet D.F., Cottet S., Lobrinus J.A., Borruat F.X., Balmer A., Munier F.L. Retinopathy in Danon disease. Arch Ophthalmol 2007; 125(2): 231–6. DOI: 10.1001/archopht.125.2.231

23. Bui Q.M., Brambatti M., Escobedo V., Nguyen N., Covarrubias E., Teng D. et al. Longitudinal echocardiographic findings of Danon disease: insights from a global registry. JACC 2019; 73(9): 983. DOI: 10.1016/S0735-1097(19)31590-6

24. Рыжкова О.П., Кардымон О.Л., Прохорчук Е.Б., Коновалов Ф.А., Масленников А.Б., Степанов В.А. Руководство по интерпретации данных последовательности ДНК человека, полученных методами массового параллельного секвенирования (MPS) (редакция 2018, версия 2). Медицинская генетика 2019; 18(2): 3–23. [Ryzhkova O.P., Cardimon O.L., Prokhorchuk E.B., Konovalov F.A., Maslennikov A.B., Stepanov V.A. Guidelines for the Interpretation of Human DNA Sequence Data Obtained by Mass Parallel Sequencing Methods (edition 2018, version 2). Meditsinskaya genetika 2019; 18(2): 3–23. (In Russ.)] DOI: 10.25557/2073-7998.2019.02.3-23